Introduction
Chronic lymphocytic leukemia (CLL) is known to be associated with various autoimmune phenomena. Autoimmune hemolytic anemia (AIHA) is the commonest manifestation of such disorders in CLL. 1, 2 Treatment of autoimmune complications of CLL is primarily based on immunosuppression with drugs such as glucocorticoids. Besides splenectomy, there are not many known, effective and established alternatives for patients failing steroid therapy, although intravenous immunoglobulin and immunosuppressive drugs have been used with varying degrees of success. 3, 4 Therefore, exploration of newer therapeutic strategies to manage AIHA associated with CLL is clearly warranted.
CLL is characterized by accumulation of clonal CD20 + B lymphocytes. The exact role of B lymphocytes in the pathogenesis of AIHA associated with CLL remains unclear. It has been suggested that complex interactions between the 'B' and the 'T' lymphocytes result in breakdown of self-tolerance, which eventually leads to the formation of antibodies against self-antigens such as erythrocytes and platelets. 5 We, therefore, considered that eradication of B lymphocytes using an anti-CD20 monoclonal antibody (rituximab) could be a reasonable strategy for managing AIHA of CLL.
Rituximab is a chimeric monoclonal antibody specifically targeted against the CD20 antigen, which is expressed by more than 90% of B cell malignancies. 6, 7 rituximab has been shown to result in a depletion of the B lymphocyte pool in vivo. 8 Although rituximab has been demonstrated to be an active therapeutic agent for the treatment of relapsed or refractory low-grade B cell non-Hodgkin's lymphoma, recently there have been reports of its efficacy in the treatment of B cell CLL. [9] [10] [11] Interestingly, rituximab has also been reported to be effective in certain non-malignant autoimmune disorders such as idiopathic thrombocytopenic purpura, AIHA and cold agglutinin disease. [12] [13] [14] [15] [16] [17] We report here our results with a rituximab-based combination chemotherapy regimen in CLL patients with steroid refractory AIHA.
Patients
Eight patients with steroid refractory AIHA of CLL were treated between December 1998 and March 2000 at our institution. All patients had received therapeutic doses of prednisone for AIHA. Six out of eight patients had been previously treated with fludarabine. Five patients who had been previously treated with alkylating agents (cyclophosphamide and/or chlorambucil), had received them essentially for the treatment of CLL. The median interval between the last treatment with an alkylating agent (either as a single agent or in a combination regimen) and receiving first cycle of RCD was 11 months (range 6-14). Patient characteristics are described in Table 1 . 
Treatment regimen (RCD)
Rituximab was given at a dose of 375/m 2 intravenously (i.v.) on day 1 (D-1). Four mg of dexamethasone was given i.v. before the rituximab infusion, 4 mg i.v. halfway through and 4 mg of dexamethasone i.v. at the end of the rituximab infusion. Cyclophosphamide at a dose of 750 mg/m 2 i.v. and 12 mg of dexamethasone i.v. were given on D-2. Twelve mg of dexamethasone was given orally from D-3 to D-7. All patients were started on allopurinol at a dose of 300 mg prior to starting the RCD regimen and for 7 days thereafter. Patients were pre-medicated with acetaminophen (650 mg p.o.) and diphenhydramine (50 mg p.o.) before the rituximab infusion. Blood products were given only to patients with symptomatic anemia and/or thrombocytopenia. Treatment cycles were repeated at 4-week intervals, until the best achievable response. Response to AIHA was evaluated by frequent blood counts and Coombs test.
Results

Initial eight patients
All patients had an improvement in their blood counts ( Table  2 and Figure 1 ). Median hemoglobin following treatment with 
Relapsed five patients
Out of the initial eight patients, five patients had a relapse of AIHA after a median of 13 months (range 7-23+). Coombs test was positive at the time of relapse in four out of five patients tested. Three out of these four patients had converted to Coombs negative after the initial treatment with RCD. One patient had remained Coombs positive even after the initial RCD treatment. Median hemoglobin on relapse was 8.0 g/dl (range 5.2-8.1). All five patients were retreated with RCD and median number of RCD cycles given was 2 (range 1-3). All five patients achieved a second remission of their AIHA following RCD (Table 3) . Median post-treatment hemoglobin was 13.4 g/dl (range 12.2-14.5) (Figure 2 ). Coombs test reconverted to negative in one out of four patients who were Coombs positive before RCD treatment. Median duration of response was 7+ months (range 3-9+). One patient had a second relapse of AIHA after 3 months and died another 3 months later of progressive CLL.
Toxicity
Adverse reactions with the first infusion of rituximab were noted in six patients. The majority of these side-effects were grade I and II in severity and included nausea (2 pts), fever (1 pt), chills (2 pts), mild headache (2 pts), itching (1 pt) and rash (1 pt). One episode of hypotension was observed. Grade IV neutropenia was noted in one patient. No dose-modification of the chemotherapy was needed in any patient.
Discussion
Steroid-refractory AIHA of CLL poses a therapeutic challenge for the treating physician. It is often associated with consider- 
Figure 2
Rise in hemoglobin following retreatment with RCD in patients with relapse of AIHA. able morbidity and mortality. Although glucocorticoids are known to be effective in most CLL patients who are first discovered to have AIHA, there are no established and effective treatment options for steroid-refractory AIHA. Splenectomy is performed in many such cases but the response rates and duration of response remain unpredictable and are generally disappointing.
Rituximab, a monoclonal antibody cytocidal to virtually all B lymphocytes expressing CD20, has been proven to be an effective treatment of indolent lymphomas. This agent has also been reported to be effective in the management of autoimmune thrombocytopenic purpura (ITP) or AIHA. Although the exact mechanism of action of rituximab in ITP and AIHA is unclear, several hypotheses have been offered. 18 Elimination of CD20 expressing pre-Ig heavy chain switched plasmablasts and a small number of post-Ig heavy chain switched plasma cells (possibly responsible for producing pathogenic auto-antibodies) following treatment with rituximab may partly explain the activity of rituximab in autoimmune disorders. 18 Rituximab may also bind to the Fc receptors on macrophages, thereby preventing the immune-mediated destruction of the autoantibody coated erythrocyte. 18 For the treatment of CLL patients with AIHA who had failed initial steroid therapy, we chose to use rituximab in a schedule and regimen different from the conventional weekly dosage for 4 or more weeks. Rituximab has been shown to sensitize malignant B lymphocytes to the cytotoxic effects of chemotherapeutic drugs in vitro. 19 Czuczmen et al 20 demonstrated improved responses in indolent lymphoma with a combination of rituximab and CHOP administered every 3 to 4 weeks, than rituximab alone. 9 Similarly, in our RCD regimen, rituximab is given at monthly intervals for 2 to 4 months and each dose is accompanied by cyclophosphamide and dexamethasone.
Our results indicate a dramatic improvement in all hematological parameters following RCD therapy in all of the eight patients who had steroid-refractory AIHA of CLL (Table 2 ). There was a significant and sustained rise in the hemoglobin following this treatment. The increase in hemoglobin was evident as early as after two cycles (Figure 1 ). Five patients who were actively hemolyzing and were strongly Coombs positive before RCD converted to Coombs negative. Treatment with RCD yielded durable and long-term response to AIHA, the median duration of response was 13 months (range 7-20+) months. Two out of eight patients remain in remission 22+ and 23+ months after being treated with RCD.
Retreatment on relapse of AIHA was also effective (Table  3) . Five patients who relapsed after a median duration of 13 months (range 7-23+) following an initial response to this regimen were retreated with RCD. All five patients once again successfully achieved a rapid and durable remission of their AIHA following retreatment ( Figure 2 ).
All eight patients had active CLL at the time of development of AIHA and, after receiving treatment with RCD, achieved a response, both to AIHA and CLL, indicating a close relationship between the activity of CLL and AIHA. This may be explained by the fact that CD5
+ lymphocytes are involved in both CLL and the autoimmune phenomenon complicating CLL. It is believed that in the presence of deficient T cell control, activated malignant B cells in CLL are able to present self-antigens (expressed by the RBCs/platelets) and stimulate the residual normal B cells to form auto-antibodies directed against these self-antigens, thereby causing autoimmune cytopenias. 9 Thus, it could be argued that elimination of CD20 + malignant B lymphocytes alone could result in resolution of AIHA and a response to CLL. We are not able to comment on the relative contribution of each agent with reasonable certainty. However, all of our patients had been previously treated with steroids, five of them had received an alkylating agent within the last year, whereas none of the patients had ever received rituximab. The incorporation of rituximab into the treatment regimen seem to have contributed to the remarkable responses observed in these patients. It is possible that administering rituximab along with cyclophosphamide and dexamethasone somehow resulted in an optimal effective immunosuppression, thus achieving a resolution of AIHA.
It is worth noting that six out of eight patients in our series who had been exposed to fludarabine in the past developed AIHA. The reported incidence of AIHA after fludarabine treatment varies from 11% to 21%. 21, 22 It has been suggested that the profound lymphocytopenia following fludarabine therapy may result in T cell subset imbalance, which in turn may favor the emergence of autoreactive T cells.
The RCD regimen was very well tolerated. All patients were able to complete the treatment and none of the patients required any dose-modification. Most of the adverse events observed were with the first dose of rituximab and were only grade 1 and 2 in severity. One patient developed hypotension that was reversed by temporarily stopping the rituximab infusion and giving intravenous fluids. Hematologic toxicity was not significant, grade 4 neutropenia was seen only in one patient.
In conclusion, steroid refractory AIHA of CLL is known to have a poor outcome. Ours is the largest series of patients with warm auto-antibody AIHA treated with a rituximabbased regimen. The encouraging results observed in our series indicate that a combination of rituximab, cyclophosphamide and dexamethasone should be considered in the management of CLL patients with steroid refractory AIHA.
